xolair - search results

If you're not happy with the results, please do another search
Xolair (omalizumab)

FDA Grants Xolair Breakthrough Therapy Designation for Food Allergies

Breakthrough Therapy Designation was granted on the basis of data from seven clinical studies assessing the efficacy and safety of Xolair against a range of food allergens including peanut, milk, egg and others.
Omalizumab + OIT

Clinical Trial to Evaluate Experimental Treatment in People Allergic to Multiple Foods

NIH and partners to assess whether Omalizumab can reduce allergic reactions.
Infighting

OIT is a Therapy, Not an Ideology

The decisions we all face as patients and caretakers depend on the individual, their allergies, their lifestyles and myriad other factors.
Dr Kari Nadeau

Must Hear: Interview with Stanford Immunologist Dr Kari Nadeau – Defeating Food Allergies

Dr Kari Nadeau, who runs the Sean Parker Center for Allergy and Asthma Research at Stanford University, takes us on a tour...
Giorgi Sisters

Must See: 'ViewFinder: Food for Thought – Food Allergies'

This documentary should be required viewing for everyone as the food allergy epidemic has affected so many in the community.
Omalizumab

Study: Treatment with Omalizumab Raises Tolerance in Patients with Severe Food Allergies

Patients reached full tolerance for 70.4% of the tested foods which were reintroduced to the patients’ diet without the need for OIT.
Infant in Mother's Arms

Study: Anti-IgE Shots During Pregnancy May Provide a Lifetime of Protection from Allergies in...

"We discovered that preventing infant mice from creating antibodies would effectively diminish the risk of allergies in their adult lives."
Xolair (omalizumab)

Study: Drug Increases Speed and Safety of OIT for Multiple Allergies

Combining omalizumab with OIT is safe and effective for treating multiple food allergies simultaneously.

Study of Rapid Peanut Desensitization with Asthma Drug

A study of a treatment combining the asthma drug Xolair® with oral desensitization therapy shows promise.